Seattle Genetics, Inc. and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at American Association for Cancer Research
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented in multiple sessions at the 104th Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C. Three data presentations highlight the rapid progress being made in ADC technology and testing.